Euromedis Competitors

Stocks . France . 
Stock . Euromedis Groupe SA
ALEMG Stock   3.92  0.01  0.26%   
Euromedis Groupe competes with Biosynex, Predilife, Bluelinea, Media Lab, and Plant Advanced; as well as few others. Analyzing Euromedis Groupe competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Euromedis Groupe to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Euromedis Groupe competition on your existing holdings.
  
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Euromedis Groupe. Your research has to be compared to or analyzed against Euromedis Groupe's peers to derive any actionable benefits. When done correctly, Euromedis Groupe's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Euromedis Groupe.

Euromedis Groupe Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Euromedis Groupe and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Euromedis and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Euromedis Groupe does not affect the price movement of the other competitor.

High positive correlations

ALTME
+ 0.81
ALMKT
MLLAB
+ 0.7
ALMKT
ALTME
+ 0.67
MLLAB
ALINS
+ 0.64
ALPAT
MLLAB
+ 0.61
ALBIO
ALMKT
+ 0.56
ALBLU
  

High negative correlations

MLLAB
- 0.68
ALPRE
ALPAT
- 0.61
ALBIO
ALMKT
- 0.56
ALPRE
ALSGD
- 0.45
ALBIO
ALTME
- 0.41
ALPRE
ALSGD
- 0.37
MLLAB

Risk-Adjusted Indicators

There is a big difference between Euromedis Stock performing well and Euromedis Groupe Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Euromedis Groupe's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ALBIO  2.73  0.23  0.04 (0.60) 2.33 
(5.77)
 7.35 
(4.41)
 24.94 
ALPRE  1.92  0.08  0.00  0.47  2.21 
(2.90)
 5.32 
(3.54)
 22.75 
ALBLU  2.06  0.00 (0.01) 0.09  2.60 
(3.24)
 4.26 
(4.26)
 17.26 
ALMKT  2.62 (0.01)(0.02) 0.06  3.50 
(2.83)
 5.98 
(4.66)
 18.38 
MLLAB  1.86 (0.05) 0.00  0.02  0.00 
 0.00 
 5.29 
(0.56)
 38.38 
ALPAT  1.31 (0.14) 0.00 (1.96) 0.00 
 0.00 
 2.41 
(2.81)
 10.35 
ALSGD  4.77 (0.07)(0.01)(0.01) 5.42 
(9.24)
 10.00 
(9.09)
 49.70 
ALAMA  2.83 (0.58) 0.00  1.00  0.00 
 0.00 
 6.25 
(8.33)
 22.29 
ALINS  1.66 (0.24) 0.00 (1.14) 0.00 
 0.00 
 3.85 
(4.00)
 12.50 
ALTME  3.34 (0.62) 0.00 (6.24) 0.00 
 0.00 
 8.85 
(6.98)
 25.36 
All Fundamental Data

Euromedis Groupe Competitive Analysis

The better you understand Euromedis Groupe competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Euromedis Groupe's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Euromedis Groupe's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ALEMG ALBIO ALPRE ALBLU ALMKT MLLAB ALPAT ALSGD ALAMA ALINS
 0.26 
 3.92 
Euromedis
 1.37 
 0.72 
Biosynex
 0.30 
 3.31 
Predilife
 4.17 
 0.50 
Bluelinea
 11.69 
 0.09 
Mauna
 0.56 
 3.56 
Media
 1.27 
 7.96 
Plant
 8.33 
 0.11 
Spineguard
 5.88 
 0.16 
AMA
 4.17 
 0.23 
Intrasense
Market Volatility
(90 Days Market Risk)
Not too volatile
Abnormally volatile
Unstable
Abnormally volatile
Out of control
Very risky
Somewhat reliable
Out of control
Out of control
Out of control
Market Performance
(90 Days Performance)
Weakest
Soft
Weak
Weak
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Low
Average
Fair
Unknown
Low
Average
Small
Unknown
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
1.94
3.47
1.22
2.01
1.93
1.17
1.72
Net Asset
268.94 M
3.97 M
6.15 M
N/A
14.88 M
11.9 M
8.77 M
Profit Margin
0.21
N/A
-0.22
0.0796
-0.24
-0.44
-0.58
EBITDA
139.33 M
(3.49 M)
(2.52 M)
187.24 K
(1.62 M)
(812.46 K)
(570 K)
Operating Margin
0.3
-12.32
-0.19
0.12
-0.46
-0.33
-0.57
Current Valuation
91.77 M
22.91 M
19.52 M
3.21 M
21.9 M
18.77 M
9.34 M
Price To Book
0.77
34.29
22.67
3.53
2.78
3.68
3.31
Retained Earnings
(5 M)
N/A
N/A
N/A
N/A
N/A
(15 M)
Current Asset
6 M
N/A
N/A
N/A
N/A
N/A
5 M
Beta
-2.01
0.24
0.77
0.62
0.74
2.71
-0.21
Number Of Employees
320
14
77
11
60
21
55
Shares Outstanding
10.25 M
3.64 M
12.24 M
2.37 M
1.09 M
31.71 M
51.78 M
Cash Flow From Operations
109.83 M
(3.83 M)
(565.52 K)
133.16 K
(388)
(1.16 M)
(903 K)
Annual Yield
0.17
N/A
N/A
0.0251
N/A
N/A
N/A
Total Debt
29.16 M
4.52 M
3.98 M
N/A
3.89 M
3.61 M
1.47 M
Return On Equity
0.89
N/A
-1.71
0.0932
-0.16
-0.43
-0.58
Z Score
3.4
2.4
2.4
N/A
1.8
5.4
7.6
Return On Asset
0.45
-0.57
-0.26
0.056
-0.0796
-0.082
-0.18
Book Value Per Share
17.24
-0.88
-0.57
0.43
5.68
0.16
0.097
Current Liabilities
4 M
N/A
N/A
N/A
N/A
N/A
3 M
Total Asset
268.94 M
3.97 M
6.15 M
N/A
14.88 M
11.9 M
8.77 M
Debt To Equity
17.7
3.79
8.7
N/A
38.7
567.9
22.9
Target Price
37.0
N/A
N/A
N/A
23.8
1.6
0.5
Last Dividend Paid
2.0
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
1.58
N/A
86.7
N/A
1.83
1.27
N/A
Market Capitalization
121.6 M
22.6 M
19.58 M
3.58 M
13.75 M
33.05 M
22.78 M
Price To Earning
48.98
N/A
-5.24
158.18
18.86
-4.81
-2.83
Price To Sales
0.46
78.81
1.65
3.01
3.76
4.11
2.42
Net Income
104 M
(3.41 M)
(3.3 M)
52.6 K
(868.29 K)
(1.72 M)
(1.2 M)
Earnings Per Share
6.37
-0.86
-0.35
0.04
1.16
-0.08
-0.08
Shares Owned By Insiders
58.06
N/A
7.32
N/A
47.91
N/A
44.94
Revenue
382.53 M
195.9 K
5.16 M
1.19 M
1.54 M
4.41 M
4.19 M
Working Capital
2 M
N/A
N/A
N/A
N/A
N/A
2 M
Cash And Equivalents
1.98 M
94.9 K
203.82 K
N/A
657.31 K
1.06 M
2.95 M
Cash Per Share
0.22
0.93
0.14
N/A
0.68
0.16
0.02
Gross Profit
206.41 M
(3.52 M)
3.18 M
233.44 K
2.52 M
3.61 M
3.52 M
Day Typical Price
3.92
0.73
3.26
0.5
0.092
3.56
7.73
0.11
0.16
0.23
Accumulation Distribution
N/A
5699.91
19.81
N/A
569504.0
N/A
46.22
N/A
N/A
2837.92
Market Facilitation Index
N/A
0.0
4.0E-4
N/A
N/A
N/A
0.0013
N/A
N/A
N/A
Daily Balance Of Power
9.2 T
(0.14)
(0.06)
9.2 T
0.7951
(9,223,372,036,855)
0.1471
(9,223,372,036,855)
(9,223,372,036,855)
(1.00)
Period Momentum Indicator
0.01
(0.01)
(0.01)
0.02
0.0097
(0.02)
0.1
(0.01)
(0.01)
(0.01)
Rate Of Daily Change
1.0
0.99
1.0
1.04
1.12
0.99
1.01
0.92
0.94
0.96
Day Median Price
3.92
0.74
3.24
0.5
0.0916
3.56
7.62
0.11
0.16
0.24
Price Action Indicator
0.005
(0.02)
0.065
0.01
0.006
(0.01)
0.39
(0.01)
(0.01)
(0.01)
Coefficient Of Variation
(84,060)
2151.52
2941.59
6574.51
11672.73
25367.69
(1,561)
132991.94
(689.18)
(1,342)
Mean Deviation
0.4238
2.73
1.92
2.06
2.62
1.86
1.31
4.77
2.83
1.66
Jensen Alpha
(0.01)
0.2302
0.082
(0)
(0.01)
(0.05)
(0.14)
(0.07)
(0.58)
(0.24)
Total Risk Alpha
(0.12)
(0.39)
(0.33)
(0.37)
(0.46)
(0.80)
(0.38)
(1.01)
(1.20)
(0.59)
Sortino Ratio
N/A
0.0351
0.004
(0.01)
(0.02)
N/A
N/A
(0.01)
N/A
N/A
Downside Variance
N/A
9.81
7.78
16.44
13.55
N/A
N/A
73.47
N/A
N/A
Standard Deviation
0.8026
4.52
3.28
3.1
3.71
6.25
1.9
7.72
4.3
2.85
Kurtosis
5.71
9.23
7.18
1.94
2.61
15.59
1.51
6.92
1.47
2.53
Potential Upside
1.02
7.35
5.32
4.26
5.98
5.29
2.41
10.0
6.25
3.85
Treynor Ratio
(0.77)
(0.60)
0.4735
0.0878
0.0632
0.0207
(1.96)
(0.01)
1.0
(1.14)
Maximum Drawdown
5.56
24.94
22.75
17.26
18.38
38.38
10.35
49.7
22.29
12.5
Variance
0.6442
20.44
10.73
9.59
13.8
39.1
3.63
59.53
18.52
8.13
Market Risk Adjusted Performance
(0.76)
(0.59)
0.4835
0.0978
0.0732
0.0307
(1.95)
0.0038
1.01
(1.13)
Risk Adjusted Performance
5.0E-4
0.0407
0.0314
0.0183
0.0141
0.0116
(0.04)
0.0096
(0.09)
(0.04)
Skewness
0.8609
2.58
1.75
0.1469
0.0889
(1.60)
0.2702
1.65
(0.28)
0.3773
Semi Deviation
N/A
2.33
2.21
2.6
3.5
N/A
N/A
5.42
N/A
N/A
Information Ratio
(0.13)
0.0243
0.0034
(0.02)
(0.02)
(0.01)
(0.12)
(0.01)
(0.17)
(0.11)
Value At Risk
(1.02)
(4.41)
(3.54)
(4.26)
(4.66)
(0.56)
(2.81)
(9.09)
(8.33)
(4.00)
Expected Short fall
N/A
(5.77)
(2.90)
(3.24)
(2.83)
N/A
N/A
(9.24)
N/A
N/A
Downside Deviation
N/A
3.13
2.79
4.05
3.68
N/A
N/A
8.57
N/A
N/A
Semi Variance
N/A
5.45
4.87
6.77
12.25
N/A
N/A
29.38
N/A
N/A

Euromedis Groupe Competition Performance Charts

Five steps to successful analysis of Euromedis Groupe Competition

Euromedis Groupe's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Euromedis Groupe in relation to its competition. Euromedis Groupe's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Euromedis Groupe in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Euromedis Groupe's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Euromedis Groupe, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Euromedis Groupe position

In addition to having Euromedis Groupe in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Value Funds Thematic Idea Now

Small Value Funds
Small Value Funds Theme
Funds or Etfs that invest in the undervalued stocks of small to mid-sized companies. The Small Value Funds theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Value Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Euromedis Stock Analysis

When running Euromedis Groupe's price analysis, check to measure Euromedis Groupe's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Euromedis Groupe is operating at the current time. Most of Euromedis Groupe's value examination focuses on studying past and present price action to predict the probability of Euromedis Groupe's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Euromedis Groupe's price. Additionally, you may evaluate how the addition of Euromedis Groupe to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY